Investigational drug · Phase 3
bb2121
Also called: BMS-986395
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Multiple Myeloma.
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
11
Any phase or sponsor naming "bb2121"
First trial start
2018
Dec 13, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "bb2121", any sponsor or status.
Conditions studied
As listed on its trial records.
- Multiple Myeloma
Approved drugs for the same conditions: Multiple myeloma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "bb2121" as an intervention, largest first.
- Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)Pivotal-lookingCompleted
CelgeneBristol Myers Squibb (BMY)
NCT03651128 · 386 participants · Start Apr 16, 2019 · Primary completion Apr 13, 2026
Drug: bb2121; Daratumumab and 7 more · For: Multiple Myeloma
Sites: Birmingham, Alabama; Scottsdale, Arizona; Los Angeles, California · 62 sites in all
CelgeneBristol Myers Squibb (BMY)
NCT03601078 · 312 participants · Start Dec 13, 2018 · Primary completion Jan 15, 2026
Drug: bb2121; Lenalomide and 1 more · For: Multiple Myeloma
Sites: Scottsdale, Arizona; San Francisco, California; Tampa, Florida · 25 sites in all
- Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple MyelomaCompleted
CelgeneBristol Myers Squibb (BMY)
NCT03361748 · 149 participants · Start Dec 13, 2017 · Primary completion Dec 20, 2023
Drug: bb2121 · For: Multiple Myeloma
Sites: San Francisco, California; Atlanta, Georgia; Boston, Massachusetts · 48 sites in all
- A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell TransplantationPivotal-lookingActive, not recruiting
CelgeneBristol Myers Squibb (BMY)
NCT06045806 · 79 participants · Start Oct 16, 2023 · Primary completion Aug 11, 2025
Drug: idecabtagene vicleucel; Lenalidomide and 2 more · For: Multiple Myeloma
Sites: Los Angeles, California; Orange, California; Sacramento, California · 101 sites in all
- Study of bb2121 in Multiple MyelomaCompleted
CelgeneBristol Myers Squibb (BMY)
NCT02658929 · 67 participants · Start Dec 22, 2015 · Primary completion Jul 22, 2019
Drug: bb2121 · For: Multiple Myeloma
Sites: Stanford, California; Bethesda, Maryland; Boston, Massachusetts · 9 sites in all
CelgeneBristol Myers Squibb (BMY)
NCT02786511 · 50 participants (planned) · Start Apr 28, 2016 · Primary completion Oct 11, 2019
Drug: Safety and efficacy assessments · For: Multiple Myeloma
Sites: Palo Alto, California; Bethesda, Maryland; Boston, Massachusetts · 9 sites in all
Medical College of WisconsinAcademic, hospital or other
NCT05032820 · 40 participants · Start Jan 5, 2022 · Primary completion Aug 22, 2024
Drug: Lenalidomide; bb2121 and 2 more · For: Multiple Myeloma
Sites: Duarte, California; Palo Alto, California; San Francisco, California · 15 sites in all
- A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell TransplantActive, not recruiting
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT05393804 · 24 participants · Start May 20, 2022 · Primary completion May 2027
Drug: Ide-cel (bb2121) · For: Multiple Myeloma
Sites: Basking Ridge, New Jersey; Middletown, New Jersey; Montvale, New Jersey · 7 sites in all
CelgeneBristol Myers Squibb (BMY)
NCT04855136 · 21 participants · Start Jun 1, 2021 · Primary completion Apr 25, 2025
Drug: BB2121; CC-220 and 1 more · For: Multiple Myeloma
Sites: Birmingham, Alabama; San Francisco, California; Jacksonville, Florida · 17 sites in all
CelgeneBristol Myers Squibb (BMY)
NCT04196491 · 13 participants · Start May 27, 2020 · Primary completion Jun 7, 2023
Drug: bb2121; Fludarabine and 2 more · For: Multiple Myeloma
Sites: Phoenix, Arizona; Los Angeles, California; San Francisco, California · 22 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Idecabtagene vicleucel manufacturing and clinical value of out-of-specification products in relapsed and refractory MM.
Sidana S, Lin Y, Cowan AJ, et al. · Blood Adv 2026
- Characterizing the exposure-response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.
Connarn JN, Witjes H, van Zutphen-van Geffen M, et al. · CPT Pharmacometrics Syst Pharmacol 2023
- Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial.
Delforge M, Otero PR, Shah N, et al. · Leuk Res 2023
- Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma.
Minakata D, Ishida T, Ando K, et al. · Int J Hematol 2023
- Structured expert elicitation to inform long-term survival extrapolations using alternative parametric distributions: a case study of CAR T therapy for relapsed/ refractory multiple myeloma.
Ayers D, Cope S, Towle K, et al. · BMC Med Res Methodol 2022
- Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial.
Shah N, Delforge M, San-Miguel J, et al. · Leuk Res 2022
Also in development for Multiple Myeloma
- EtentamigABBV-383, TNB-383BPhase 38 trials
AbbVie · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Amyloid Light Chain (AL) Amyloidosis
- BMS-986348CC-92480, mezigdomidePhase 37 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- GR1803Velinotamig specified specified days., CLN-803Phase 37 trials
Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Multiple Myeloma, Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
- JNJ-79635322Ramantamig, BCMAxGPRC5DxCD3Phase 37 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- Cilta-celJNJ-68284528Phase 36 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- Anitocabtagene AutoleucelCART-ddBCMAPhase 34 trials
Gilead Sciences · Multiple Myeloma, Newly Diagnosed Multiple Myeloma
- CevostamabRO7187797Phase 34 trials
Roche (Genentech) · Multiple Myeloma
- IBI3003Phase 34 trials
Innovent Biologics (Suzhou) Co. Ltd. · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.